New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2013
Today's noteworthy downgrades include: Abaxis (ABAX) downgraded to Underperform from Neutral at BofA/Merrill... Aeropostale (ARO) downgraded to Hold from Buy at KeyBanc... Affymax (AFFY) downgraded to Neutral from Outperform at RW Baird... Ascena Retail (ASNA) downgraded to Hold from Buy at KeyBanc... Berry Petroleum (BRY) downgraded to Neutral from Positive at Susquehanna... Endo Health (ENDP) downgraded to Underweight from Neutral at Piper Jaffray... GulfMark Offshore (GLF) downgraded to Buy from Strong Buy at ISI Group... NV Energy (NVE) downgraded to Hold from Buy at Wunderlich... Noble Energy (NBL) downgraded to Buy from Conviction Buy at Goldman... SM Energy (SM) downgraded to Market Perform from Outperform at BMO Capital... Tidewater (TDW) downgraded to Neutral from Buy at ISI Group... PetSmart (PETM) downgraded to Equal Weight from Overweight at Johnson Rice... Depomed (DEPO) downgraded to Hold from Buy at WallachBeth... BP (BP) downgraded to Buy from Strong Buy at ISI Group... Children's Place (PLCE) downgraded at Janney Capital... Dynavax (DVAX) downgraded to Hold from Buy at MLV Equity... Teekay LNG (TGP) downgraded at Raymond James... Commerce Bancshares (CBSH) downgraded at Raymond James... Alcatel-Lucent (ALU) downgraded to Underweight from Neutral at HSBC... Teva (TEVA) downgraded to Hold from Buy at Argus... Owens Corning (OC) downgraded to Market Perform from Outperform at Wells Fargo... Heinz (HNZ) downgraded to Neutral from Buy at Citigroup... Williams Partners (WPZ) downgraded to Accumulate from Buy at Global Hunter.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 >>
September 28, 2015
09:30 EDTWPZEnergy Transfer Equity expects to form LNG affiliate in 2016
Subscribe for More Information
08:08 EDTENDPACETO subsidiary acquires three ANDAs from Endo
Subscribe for More Information
08:03 EDTBPBP initiated with an Outperform at BMO Capital
07:52 EDTTEVAIIR Holdings to hold a conference
Subscribe for More Information
07:46 EDTTEVAUBS to hold a field trip
Subscribe for More Information
07:25 EDTNBLJohnson Rice to hold a conference
2015 Johnson Rice Energy Conference is being held in New Orleans, Louisiana on September 28-30.
07:10 EDTWPZWilliams Partners announces termination of merger agreement with Williams
Subscribe for More Information
07:07 EDTWPZEnergy Transfer Equity sees Williams deal immediately accretive to cash flow
At closing, the transaction will be immediately accretive to distributable cash flow and distributions per unit for ETE and is expected to be credit positive to ETE's credit ratings; ETE's distribution growth rate is expected to remain at its current level; As a result of diligence, the size of both the expected cost savings and the anticipated commercial synergies exceeds ETE's previous expectations and will help ensure that the duration of ETE's distribution growth rate will be longer as a result of the transaction. There is no expected impact to WPZ's credit ratings as a result of the ETE/Williams combination; WPZ unitholders will have greater distributable cash flow from material cost savings and synergies of up to $400 million per annum with WPZ joining the Energy Transfer shared service model; the combination will create new commercial opportunities for WPZ, including the potential to acquire assets from the overall Energy Transfer group, that will improve WPZ's business outlook, cash flow growth and overall financial profile; WPZ unitholders will benefit from having a general partner, ETE, that, based on the unique intrinsic financial and strategic optionality in the Energy Transfer family, will be in a position to help WPZ fully realize its long-term growth potential; and WPZ will receive a $428 million break-up fee for the termination of its merger agreement with WMB payable to all outstanding limited partnership units of WPZ including WMB's approximate 60 percent ownership.
07:05 EDTWPZWilliams Partners, Williams withdraw financial guidance
Subscribe for More Information
07:04 EDTWPZEnergy Transfer Equity to combine with Williams in $37.7B transaction
Subscribe for More Information
07:02 EDTWPZEntergy Transfer Equity to combine with Williams
Subscribe for More Information
06:44 EDTENDPEndo to host conference call
Subscribe for More Information
06:44 EDTDEPODepomed issues statement on ISS report
Depomed (DEPO) issued the following statement regarding a report by Institutional Shareholder Services' on Horizon Pharma's (HZNP) solicitation to call two special meetings of Depomed's shareholders. Depomed commented, "The ISS recommendation does not change the fact that we believe Horizon's offer does not reflect the value inherent in Depomed's business nor Depomed's compelling prospects for long-term growth and value creation, and therefore is not in the best interests of shareholders... We strongly believe Depomed shareholders are being misled by Horizon and are entitled to know the facts. First, based on Friday's closing price of Horizon stock, Horizon's all-stock exchange offer has a current value of only $21.64 per Depomed share, nowhere near the $33.00 a share that Horizon continues to disingenuously tout in its communications to Depomed shareholders. Second, Horizon has misleadingly announced false deadlines to submit proxies. To be clear, Depomed's Board of Directors has set record dates for October 29 and November 13, 2015 and there is no deadline approaching for Depomed shareholders to submit proxy cards to call a special meeting. Moreover, there is absolutely no requirement for Depomed shareholders to take any action until after the October 29 and November 13, 2015 record dates."
06:39 EDTENDPEndo sees Q3 revenue $720M-$740M, consensus $754.1M
The operations from Par are not expected to have a material impact on Q3 results. Sees Q3 adjusted interest expense of approximately $95M. Sees Q3 adjusted effective tax rate of 2%-4%.
06:39 EDTENDPEndo raises FY15 adjusted EPS to $4.50-$4.60 from $4.40-$4.60, consensus $4.52
Subscribe for More Information
06:37 EDTENDPEndo sees FY16 adjusted EPS $5.85-$6.15, consensus $5.71
Subscribe for More Information
06:37 EDTENDPEndo completes acquisition of Par Pharmaceutical
Subscribe for More Information
06:20 EDTBPBP not concerned over hostile takeover due to Macondo disclaimer, Bloomberg says
BP, which is allegedly readying defenses for potential acquisition offers, isn't concerned about a hostile takeover because of a disclaimer in its Macondo spill settlement that could put $12.6B onto the price tag, Bloomberg reports. A potential buyer may have to accelerate the payment of as much as two-thirds of the $18.7B in penalties BP agreed to pay the U.S. and several states, the report says, citing company filings. An option that provides the government and certain states the power to demand faster payment in a takeover basically hands them a veto over any deal, the report says. Reference Link
05:26 EDTTEVATeva announces approval of Copaxone in Japan
Teva announced the approval by the Japanese Ministry of Health, Labour and Welfare of once-daily COPAXONE 20mg injection for the prevention of relapse of multiple sclerosis . The product will be commercialized in Japan by Takeda Pharmaceutical Company Limited. In Japan, glatiramer acetate was developed as an Unapproved New Drug by Teva Pharmaceutical K.K., a wholly owned subsidiary of Teva, at the request of the MHLW. In March, 2013, Takeda and Teva signed an agreement in which Teva granted Takeda the right to commercialize COPAXONE in Japan. The Japanese approval for COPAXONE is based on the safety and efficacy results of an open-label, 52-week clinical trial conducted by Teva Pharmaceutical K.K. in patients with relapsing-remitting multiple sclerosis in Japan as well as the pivotal trial data sets used for approvals in other countries.
September 27, 2015
16:53 EDTTEVATeva reports Phase 3 data on reslizumab for asthma exacerbations
Teva Pharmaceutical presented results from a post hoc analysis of two pivotal Phase 3 clinical trials showing that treatment with reslizumab reduced clinical asthma exacerbations by 75% versus placebo in a subgroup of patients with late onset asthma with elevated blood eosinophils, who were inadequately controlled on inhaled corticosteroids. Reslizumab is a humanized anti-interleukin-5 monoclonal antibody. Results were pooled from two Phase 3 clinical trials that investigated reslizumab IV 3mg/kg in patients who had at least one asthma exacerbation within the previous year. In the subgroup with late onset asthma, reslizumab showed a 75% reduction in asthma exacerbations and improvement in lung function as measured by forced expiratory volume in one second. In the overall pooled patient population, asthma exacerbations were reduced by 54%, and in the subgroup of subjects diagnosed with asthma at less than 40 years of age, exacerbations were reduced by 42%. Common adverse events in the reslizumab treatment group were comparable to placebo.
1 | 2 | 3 | 4 | 5 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use